BrainStorm Cell Therapeutics, Inc. BCLI
2015 is upon us and our first order of business is to address one of the stocks we tagged in Wednesday’s premarket report. BCLI had a strong session, as it pushed its way up from an early low of 4.02 to an aftyernoon high of 4.94; a solid +23% performance.
The strong session was apparently aided by the pre-emptive PR the company released which served as a reminder that results from Phase 2a trials of its ALS (Lou Gehrig’s Disease) treatment would be released on Monday. This morning the stock is gapping up wildly as anticipation grows, having already hit a premarket high of 7.28, which represents a total increase of 81% over the low we observed on New Year’s Eve.
Monday’s data release, which is expected to be positive, should most likely produce one of two effects. Either the results will beat expectations and facilitate another strong move, or they will fail to meet the mark and cause a pullback. In case of the latter, there may be rebound opportunities waiting just around the corner.
RedHill BioPharma Ltd. RDHL & NephroGenex, Inc. NRX
We also had this pair of standouts appear in Wednesday’s report, with each stock making a similar move. Both started the day with significant spikes in PPS, followed by a tapering off into the close.
RDHL made a sensational jump beginning almost immediately at the open running from 12.52 on up to 17.85 before its pullback, an intraday spike equaling 42.5%. Coincidentally, the stock ended the session having traded 42.5X its 3-month average volume.
NRX saw an initial low of 12.96, followed by a healthy 39% run to a high of 17.98. This play would offer one more opportunity in the form of an intraday swing as it came down and rebounded off of the 12.60-mark before returning to 15.15, an added 20% move, bringing the day’s cumulative total of possible gains to 59% .
Extended Watchlist:
CUR, ARWR, CLF, MSTX, RAD